MBM Wealth Consultants LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 6.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,363 shares of the company’s stock after purchasing an additional 213 shares during the period. MBM Wealth Consultants LLC’s holdings in Johnson & Johnson were worth $501,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of JNJ. Nordea Investment Management AB increased its holdings in Johnson & Johnson by 88.0% in the 2nd quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock worth $2,382,514,000 after purchasing an additional 8,062,204 shares in the last quarter. BlackRock Inc. increased its holdings in Johnson & Johnson by 0.6% in the 2nd quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock worth $27,242,005,000 after purchasing an additional 1,168,129 shares in the last quarter. California Public Employees Retirement System increased its holdings in Johnson & Johnson by 8.9% in the 3rd quarter. California Public Employees Retirement System now owns 10,616,780 shares of the company’s stock worth $1,580,626,000 after purchasing an additional 864,547 shares in the last quarter. MUFG Securities EMEA plc increased its holdings in Johnson & Johnson by 124.7% in the 2nd quarter. MUFG Securities EMEA plc now owns 1,506,456 shares of the company’s stock worth $211,853,000 after purchasing an additional 836,139 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its holdings in Johnson & Johnson by 290.9% in the 2nd quarter. Handelsbanken Fonder AB now owns 1,114,004 shares of the company’s stock worth $156,662,000 after purchasing an additional 829,053 shares in the last quarter. 67.44% of the stock is owned by institutional investors and hedge funds.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is owned by company insiders.
Shares of NYSE:JNJ opened at $143.68 on Friday. The business’s 50 day simple moving average is $145.31 and its two-hundred day simple moving average is $146.47. The firm has a market cap of $378.24 billion, a P/E ratio of 22.59, a PEG ratio of 3.04 and a beta of 0.69. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. Johnson & Johnson has a 52-week low of $109.16 and a 52-week high of $157.00.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The company had revenue of $21.08 billion for the quarter, compared to analyst estimates of $20.15 billion. During the same quarter last year, the company earned $2.12 earnings per share. The company’s revenue for the quarter was up 1.7% on a year-over-year basis. On average, equities analysts forecast that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.01 dividend. The ex-dividend date is Monday, November 23rd. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.81%. Johnson & Johnson’s dividend payout ratio is presently 46.54%.
A number of brokerages have issued reports on JNJ. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Cantor Fitzgerald increased their price target on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Credit Suisse Group increased their price target on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a research note on Friday, November 20th. Finally, Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $164.93.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Story: Day Trading
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.